ClinicalTrials.gg
CompletedNCT02783183Updated Jan 16, 2019

A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin

A Phase 1 interventional study of YHD1119 and Lyrica in Peripheral Nueropathy Pain, sponsored by Yuhan Corporation. Completed. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-16.

Sponsored by Yuhan Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing pregabalin in Pain — 4 open to participants now, 4 under way, none of them phase 3. Pregabalin · Pain.

Enrollment
42nd of 55
32 · median 64
Started
2016
with 4 others
Phase 1
3 of 55
none open now
Registered
42nd of 55
by date
Lead sponsor
2 of 55
Yuhan Corporation

Among the 55 studies testing pregabalin in Pain, this one is the 42nd largest by enrollment, is one of 5 that started in 2016, is one of 3 in phase 1, and was the 42nd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 55 studies testing pregabalin in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 19 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing pregabalin in Pain, or all of them as a file.
02

Study summary

The purpose of this trial to compare the pharmacokinetic characteristics of YHD1119(Pregabalin 300mg) and Lyrica capsule(Pregabalin 150mg). YHD1119 is controlled release formulation which is made by Yuhan Corporation. Primary endpoints are Cmax,ss and AUCtau and secondary endpoints are AUClast,ss, AUCinf,ss, Tmax,ss and t1/2.

03

Conditions studied

  • Peripheral Nueropathy Pain

Browse trials for

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19\~50 years old, healthy male volunteers
  • >55Kg(Body weight) and 18.5\<\<28

Exclusion criteria

Exclusion Criteria:

  • or ALT > 3 * Upper normal range (Lab)
  • Total > 2.0 mg/dl
  • Systolic BP >140 OR \<90, Diastolic BP >100 OR \<60
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    YHD1119

    Pregabalin 300mg

    Drug: YHD1119 · Drug: Lyrica

  • Active comparator
    Lyrica

    Pregabalin 150mg

    Drug: YHD1119 · Drug: Lyrica

Interventions

  • 2 by 2

    Also known as: Pregabalin 300mg

  • DrugLyrica

    2 by 2

    Also known as: Pregabalin 150mg

06

What researchers measure

Primary outcomes

  1. Cmax,ss

    Time frame: 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours

  2. AUCtau

    Time frame: 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours

Secondary outcomes

  1. AUClast,ss

    Time frame: 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours

  2. AUCinf,ss

    Time frame: 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours

  3. Tmax,ss

    Time frame: 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Moon SJ, Jeon JY, Lim Y, An T, Jang SB, Kim S, Na WS, Lee SY, Kim MG. Pharmacokinetics of a New, Once-Daily, Sustained-release Pregabalin Tablet in Healthy Male Volunteers. Clin Ther. 2021 Aug;43(8):1381-1391.e1. doi: 10.1016/j.clinthera.2021.06.010. Epub 2021 Jul 11. PubMed 34256964 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Aug 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2016
First posted
May 26, 2016
Start
Jun 2016
Primary completionActual
Aug 2016
CompletionActual
Nov 2016
Last update
Jan 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02783183
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
May 26, 2016
Start date
Jun 2016
Primary completion
Aug 2016
Completion
Nov 2016
Last update
Jan 16, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion